New cocktail aims to tame recurrent brain cancer
NCT ID NCT04421560
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 31 times
Summary
This study tests a combination of three drugs—pembrolizumab, ibrutinib, and rituximab—in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can stop the cancer from growing for at least 6 months. About 37 participants will receive the drugs, and researchers will monitor side effects and how well the cancer responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
-
Columbia University Medical Center
WITHDRAWNNew York, New York, 10032, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab, Ibrutinib, and Rituximab
What this could lead to
If this works, it could offer a new treatment option for people with relapsed primary CNS lymphoma, potentially controlling the disease for longer.
What could go wrong
This is an early-phase trial with only 37 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not expected to be a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.